Relay Therapeutics, Inc.
NASDAQ:RLAYBiotechnology
+$0.41 today
- Market cap
- $3.65B
- Beta
- 1.75
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$1.52
Volume 2.43M
Average 3.70M
RLAY Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Relay Therapeutics, Inc.NASDAQ: RLAY
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures turns positive
Q2 FY2026 capital expenditures was $0, compared with -$26K a year earlier. Trailing-twelve-month capital expenditures was $0. Over 3 fiscal years it compounded at -64.4% a year.
Context
- Capital expenditures amounted to 2.7% of revenue in FY2025, down 17.5 pp from a year earlier.
- Capital expenditures grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly capital expenditures holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (410K) USD
- Year-over-year change
- +79.7%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (410K) | +79.7% |
| FY2024 | 2024-12-31 | (2.02M) | +51.1% |
| FY2023 | 2023-12-31 | (4.13M) | +54.5% |
| FY2022 | 2022-12-31 | (9.06M) | -161.1% |
| FY2021 | 2021-12-31 | (3.47M) | — |
Capital Expenditures vs competitors
How RLAY compares with its peers on the latest reported figures
- RLAY's LTM Jun 2026 capital expenditures of $0 is the 10th largest of the 11 companies compared; the peer median is $393K.
- Its year-over-year change of +100.0% is the highest of 10, against a peer median of -48.1%.
- Capital expenditures amounts to 0.0% of revenue for RLAY, versus a peer median of 1.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $9.5M | -13.4% | +4.6% | 1.4% | |
| LTM Jun 2026 | $9.1M | -41.1% | +13.9% | — | |
| LTM Mar 2026 | $2.01M | -48.1% | -11.7% | 0.9% | |
| LTM Jun 2026 | $1.19M | -37.5% | -20.1% | 1.1% | |
| LTM Mar 2026 | $487K | -64.1% | -30.0% | — | |
| LTM Sep 2026 | $299K | -68.5% | -48.5% | — | |
| LTM Mar 2026 | $215K | -60.3% | -36.8% | — | |
| LTM Sep 2026 | $132K | +10.9% | -80.2% | — | |
| LTM Mar 2026 | $20K | -96.2% | -71.9% | 0.1% | |
| LTM Jun 2026 | $0 | +100.0% | -64.4% | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding RLAY) | $393K | -48.1% | -30.0% | 1.0% | |
Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (363.87M) | (290.51M) | (341.97M) | (337.71M) | (276.48M) |
| Depreciation & Amortization | 3.93M | 4.13M | 5.27M | 5.46M | 3.56M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 48.45M | 56.14M | 86.03M | 94.14M | 62.42M |
| Change in Working Capital | 97.34M | 11.25M | (32.46M) | 14.62M | (23.31M) |
| Accounts Receivables | 77.79M | 97K | 5.22M | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 930K | 1.99M | (2.39M) | 0 | (11.44M) |
| Other Working Capital | 18.62M | 9.16M | (35.28M) | 14.62M | (11.87M) |
| Other Non-Cash Items | 139.74M | (10.5M) | (17.19M) | (25.62M) | (1.65M) |
| Operating Cash Flow | (74.41M) | (229.49M) | (300.32M) | (249.11M) | (235.46M) |
| Capital Expenditures | (3.47M) | (9.06M) | (4.13M) | (2.02M) | (410K) |
| Acquisitions (Net) | (25.3M) | 179.68M | 0 | 0 | 0 |
| Purchases of Investments | (980.67M) | (535.42M) | (385.54M) | (650.63M) | (122.97M) |
| Sales of Investments | 529.92M | 355.74M | 647.3M | 611.56M | 316.18M |
| Other Investing Activities | 0 | (179.68M) | 0 | 0 | 0 |
| Investing Cash Flow | (479.51M) | (188.75M) | 257.63M | (41.08M) | 192.8M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 382.21M | 284.74M | 30.28M | 265.89M | 1.6M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.88M | 5.17M | 4.47M | 4.26M | 0 |
| Financing Cash Flow | 388.09M | 289.91M | 34.75M | 270.15M | 1.6M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (165.83M) | (128.33M) | (7.93M) | (20.04M) | (41.05M) |
| Free Cash Flow | (77.88M) | (238.55M) | (304.44M) | (251.13M) | (235.87M) |
Relay Therapeutics, Inc.
NASDAQ:RLAY
Intrinsic Alpha fair value
Locked
Current Price
$16.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.